SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Robert L. Ray who wrote (23124)7/14/1998 12:40:00 AM
From: Henry Niman  Respond to of 32384
 
Robert, LGND seems to be more interested in oral formulations for Panretin than topical ones. I'm not sure why, but it would seem that topical panretin would have some strong indications for skin disorders like psoriasis and acne, but LGND does not seem to be aggressively targeting such indications (they have oral but not topical Panretin trials announced for skin diseases).